Increased transforming growth factor β and interleukin 10 transcripts in peripheral blood mononuclear cells of colorectal cancer patients.
Increased transforming growth factor β and interleukin 10 transcripts in peripheral blood mononuclear cells of colorectal cancer patients.
复制标题
DOI：
10.5114/wo.2016.65605
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Stanilova SA
中科院分区：
文献类型：
--
作者：
Stanilov NS;Miteva L;Cirovski G;Stanilova SA
外周血中免疫细胞产生某些细胞因子的能力影响肿瘤引发的炎症。本研究旨在探讨白细胞介素12A （IL-12A）、IL-12B、IL-23A、IL-10、IL-6、转化生长因子β (TGF-β)、HDAC3和iNOS在结直肠癌（CRC）患者外周血单核细胞（PBMC）中的表达情况。术前和术后10天采集结直肠癌患者静脉血进行PBMC分离。分离总RNA和合成cDNA后，进行实时荧光定量PCR检测。我们的研究结果表明，在所研究的细胞因子基因中，IL-10和TGF-β在结直肠癌患者中与对照组相比显著上调，而IL-23 mRNA的表达在结直肠癌患者中显著降低。我们观察到CRC患者术前PBMC中IL-10和TGF-β mRNA水平与术后和对照组相比均显著升高。我们还发现，与晚期结直肠癌相比，早期的iNOS显著上调。基于这些结果，我们可以假设CRC患者的PBMC基因表达编程驱动Th细胞向Treg而不是Th1抗肿瘤亚群的局部分化。
The ability of immune cells in peripheral blood to produce certain cytokines affects tumour-elicited inflammation. The aim of this study was to investigate the gene expression of interleukin 12A (IL-12A), IL-12B, IL-23A, IL-10, IL-6, transforming growth factor β (TGF-β), HDAC3, and iNOS in peripheral blood mononuclear cells (PBMC) from colorectal cancer (CRC) patients. The venous blood for PBMC isolation was collected preoperatively and 10 days after surgery, from CRC patients. After isolation of total RNA and synthesis of cDNA, quantitative real-time PCR assays were performed. Our results demonstrated that among investigated cytokine genes IL-10 and TGF-β were significantly upregulated in patients with CRC compared to the control group, while the expression of IL-23 mRNA was significantly decreased in CRC patients. We observed significantly increased mRNA levels in CRC patients’ PBMC before surgery for IL-10 and TGF-β compared to both postoperative and control groups. We also found a significant upregulation of iNOS in early compared to advanced CRC. Based on the results we can assume that PBMC gene expression programming in CRC patients drives local differentiation of Th cells towards Treg instead of the Th1 anti-tumour subpopulation.